Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTS,S/AS01B with or without ChAd63/MVA ME-TRAP malaria sporozoite challenge study
2013-000393-30Phase 2Completed
- Sponsor
- University of Oxford
- Start
- May 2013
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of RTS,S, ChAd63 ME-TRAP and MVA ME-TRAP in Falciparum malaria (PF) (4 arms), sponsored by University of Oxford. Primary endpoints: Protective efficacy after controlled human malaria infection and Safety of Group 1 vaccination schedule. Started May 2013; status: completed.
02
Drugs
RTS,SChAd63 ME-TRAPMVA ME-TRAP
03
Conditions
Falciparum malaria (PF)
Beyond the preview
Go deeper on 2013-000393-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000393-30.